News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Japan Patent Office Issues Advaxis, Inc. A Notice Of Allowance For Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology


4/14/2014 8:48:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J., April 14, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES